Lymphocyte responsiveness to urinary glycosaminoglycan in systemic scleroderma

Area of Science:

• Immunology
• Rheumatology
• Biochemistry

Background:

• Systemic scleroderma is a complex autoimmune disease characterized by skin thickening and internal organ fibrosis.
• Previous research isolated a unique glycosaminoglycan from the urine of scleroderma patients that induced scleroderma-like skin changes in mice.
• The immunological role of this specific urinary glycosaminoglycan in scleroderma pathogenesis remained unclear.

Purpose of the Study:

• To investigate the cell-mediated immune response to a previously identified scleroderma-associated urinary glycosaminoglycan.
• To determine if lymphocytes from scleroderma patients exhibit a specific response to this urinary glycosaminoglycan.
• To differentiate the immune response to this glycosaminoglycan from responses in other connective tissue diseases and healthy individuals.

Main Methods:

• Lymphocyte transformation test was employed to assess cell-mediated immune responses.
• Lymphocytes were isolated from patients diagnosed with systemic scleroderma, systemic lupus erythematosus (SLE), dermatomyositis, and from healthy controls.
• The response of lymphocytes was measured upon exposure to the isolated scleroderma-inducing urinary glycosaminoglycan and to glycosaminoglycans from normal urine.

Main Results:

• Lymphocytes from patients with systemic scleroderma showed a significant transformation response when incubated with the scleroderma-inducing urinary glycosaminoglycan.
• Lymphocytes from patients with SLE, dermatomyositis, and healthy individuals exhibited minimal to no response to this specific glycosaminoglycan.
• Urinary glycosaminoglycans from healthy individuals did not stimulate lymphocytes from either scleroderma patients or healthy controls.

Conclusions:

• The study demonstrates a specific cell-mediated immune response in scleroderma patients to a unique urinary glycosaminoglycan.
• This finding suggests that the scleroderma-associated urinary glycosaminoglycan may play a role in the immunopathogenesis of systemic scleroderma.
• The results highlight the potential of this glycosaminoglycan as a biomarker or therapeutic target in scleroderma research.